MedImmune, LLC - Product Pipeline Review - 2016

Published: Apr, 2016 | Pages: 164 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

MedImmune, LLC - Product Pipeline Review - 2016

Summary

Global Markets Direct's, ‘MedImmune, LLC - Product Pipeline Review - 2016', provides an overview of the MedImmune, LLC's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by MedImmune, LLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of MedImmune, LLC
- The report provides overview of MedImmune, LLC including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses MedImmune, LLC's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features MedImmune, LLC's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy

- Evaluate MedImmune, LLC's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for MedImmune, LLC
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding MedImmune, LLC's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Content
Table of Contents 2

List of Tables 5
List of Figures 5
MedImmune, LLC Snapshot 6
MedImmune, LLC Overview 6
Key Information 6
Key Facts 6
MedImmune, LLC - Research and Development Overview 7
Key Therapeutic Areas 7
MedImmune, LLC - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Pipeline Products - Out-Licensed Products 19
MedImmune, LLC - Pipeline Products Glance 21
MedImmune, LLC - Late Stage Pipeline Products 21
MedImmune, LLC - Clinical Stage Pipeline Products 23
MedImmune, LLC - Early Stage Pipeline Products 27
MedImmune, LLC - Drug Profiles 30
MEDI-550 30
anifrolumab 32
benralizumab 34
durvalumab 37
durvalumab + tremelimumab 41
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine 43
moxetumomab pasudotox 44
tralokinumab 46
inebilizumab 48
dusigitumab 51
INO-3112 53
mavrilimumab 55
MEDI-2070 57
MEDI-3902 58
MEDI-4893 59
MEDI-6012 61
MEDI-7510 63
MEDI-8852 65
MEDI-8897 66
tremelimumab 67
inebilizumab + MEDI-0680 70
MEDI-0382 71
AMG-211 72
AMP-110 74
AMP-224 76
durvalumab + gefitinib 78
durvalumab + MEDI-0680 79
durvalumab + MEDI-6383 80
inebilizumab + rituximab 81
MEDI-0562 82
MEDI-0639 84
MEDI-0680 85
MEDI-1814 86
MEDI-1873 87
MEDI-3617 88
MEDI-3617 + tremelimumab 89
MEDI-4166 90
MEDI-4276 91
MEDI-4920 92
MEDI-6383 93
MEDI-7836 94
MEDI-8111 95
MEDI-9197 96
MEDI-9447 97
Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma 98
respiratory syncytial virus vaccine 1 100
respiratory syncytial virus vaccine 2 101
MEDI-5117 102
264-RAD 103
Biologics for Acute Coronary Syndrome 104
EVT-770 105
MEDI-5304 106
MEDI-9314 107
Monoclonal Antibody Conjugates to Inhibit DNA Synthesis for Solid and Hematological Tumors 108
Monoclonal Antibody to Inhibit ILT7 for Systemic Lupus Erythematosus 109
PRO-391 110
V-2L2MD 111
ALM 112
Monoclonal Antibodies for Cancer 113
Monoclonal Antibody to Antagonize ECA for Enterobacteriaceae Infections 114
Recombinant Proteins for Cancer 115
MedImmune, LLC - Pipeline Analysis 116
MedImmune, LLC - Pipeline Products by Target 116
MedImmune, LLC - Pipeline Products by Route of Administration 119
MedImmune, LLC - Pipeline Products by Molecule Type 120
MedImmune, LLC - Pipeline Products by Mechanism of Action 121
MedImmune, LLC - Recent Pipeline Updates 124
MedImmune, LLC - Dormant Projects 145
MedImmune, LLC - Discontinued Pipeline Products 148
Discontinued Pipeline Product Profiles 149
MedImmune, LLC - Company Statement 153
MedImmune, LLC - Locations And Subsidiaries 155
Head Office 155
Other Locations & Subsidiaries 155
MedImmune, LLC - Key Manufacturing Facilities 157
Appendix 158
Methodology 158
Coverage 158
Secondary Research 158
Primary Research 158
Expert Panel Validation 158
Contact Us 158
Disclaimer 159

List of Tables

MedImmune, LLC, Key Information 11
MedImmune, LLC, Key Facts 11
MedImmune, LLC - Pipeline by Indication, 2016 14
MedImmune, LLC - Pipeline by Stage of Development, 2016 19
MedImmune, LLC - Monotherapy Products in Pipeline, 2016 20
MedImmune, LLC - Combination Treatment Modalities in Pipeline, 2016 21
MedImmune, LLC - Partnered Products in Pipeline, 2016 22
MedImmune, LLC - Partnered Products/ Combination Treatment Modalities, 2016 23
MedImmune, LLC - Out-Licensed Products in Pipeline, 2016 24
MedImmune, LLC - Out-Licensed Products/ Combination Treatment Modalities, 2016 25
MedImmune, LLC - Pre-Registration, 2016 26
MedImmune, LLC - Phase III, 2016 27
MedImmune, LLC - Phase II, 2016 28
MedImmune, LLC - Phase I, 2016 29
MedImmune, LLC - Phase 0, 2016 31
MedImmune, LLC - IND/CTA Filed, 2016 32
MedImmune, LLC - Preclinical, 2016 33
MedImmune, LLC - Discovery, 2016 34
MedImmune, LLC - Pipeline by Target, 2016 121
MedImmune, LLC - Pipeline by Route of Administration, 2016 124
MedImmune, LLC - Pipeline by Molecule Type, 2016 125
MedImmune, LLC - Pipeline Products by Mechanism of Action, 2016 126
MedImmune, LLC - Recent Pipeline Updates, 2016 129
MedImmune, LLC - Dormant Developmental Projects,2016 150
MedImmune, LLC - Discontinued Pipeline Products, 2016 153
MedImmune, LLC, Other Locations 160
MedImmune, LLC, Subsidiaries 161
MedImmune, LLC, Key Manufacturing Facilities 162